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Abstract
Retinoid acid receptor-related Orphan Receptor Alpha (RORA) was recently identified as a susceptibility gene for asthma in
a genome-wide association study. To investigate the impact of RORA on asthma susceptibility, we performed a genetic
association study between RORA single nucleotide polymorphisms (SNPs) in the vicinity of the asthma-associated SNP
(rs11071559) and asthma-related traits. Because the regulatory region of a previously implicated asthma susceptibility gene,
Neuropeptide S receptor 1 (NPSR1), has predicted elements for RORA binding, we hypothesized that RORA may interact
biologically and genetically with NPSR1. 37 RORA SNPs and eight NPSR1 SNPs were genotyped in the Swedish birth cohort
BAMSE (2033 children) and the European cross-sectional PARSIFAL study (1120 children). Seven RORA SNPs confined into
a 49 kb region were significantly associated with physician-diagnosed childhood asthma. The most significant association
with rs7164773 (T/C) was driven by the CC genotype in asthma cases (OR= 2.0, 95%CI 1.36–2.93, p = 0.0003 in BAMSE; and
1.61, 1.18–2.19, p = 0.002 in the combined BAMSE-PARSIFAL datasets, respectively), and strikingly, the risk effect was
dependent on the Gln344Arg mutation in NPSR1. In cell models, stimulation of NPSR1 activated a pathway including RORA
and other circadian clock genes. Over-expression of RORA decreased NPSR1 promoter activity further suggesting
a regulatory loop between these genes. In addition, Rora mRNA expression was lower in the lung tissue of Npsr1 deficient
mice compared to wildtype littermates during the early hours of the light period. We conclude that RORA SNPs are
associated with childhood asthma and show epistasis with NPSR1, and the interaction between RORA and NPSR1 may be of
biological relevance. Combinations of common susceptibility alleles and less common functional polymorphisms may
modify the joint risk effects on asthma susceptibility.
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Introduction
The Retinoic acid receptor-related Orphan Receptor Alpha
(RORA; MIM 600825, chromosome 15q22.2) was recently
implicated in asthma susceptibility by a genome-wide association
study (GWAS) [1]. In humans, RORA encodes four isoforms
(RORA-1, RORA-2, RORA-3, and RORA-4) [2], and the
asthma-associated single nucleotide polymorphism (SNP)
rs11071559 is located in the first intron of the transcript variant
encoding RORA-1. RORA is a transcription factor that belongs to
the nuclear hormone-receptor superfamily (NR1) and binds as
monomers to specific hormone response elements (RORE) in
DNA. By interacting with co-activators and co-repressors [3],
RORA might enhance or repress the transcription of target genes
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[4–10]. RORA is mostly known for its functions as a regulator of
circadian rhythms, metabolism, as well as mood disorders, and its
role in the immune system and asthma has gained attention only
recently [3,11]. RORA mRNA expression is positively correlated
with gestational age and is differentially expressed during human
lung development [12]. The mice deficient of Rora (‘‘Staggerer’’,
Rora sg/sg) showed attenuated pulmonary infiltration, less mucous
hyperplasia and reduced levels of T helper type 2 (Th2) cytokines
interleukin 4 (IL-4), IL-5 and IL-13 in a model of ovalbumin-
induced airway inflammation [13]. In addition, RORA partici-
pates in the lineage commitment of Th17 cells [14,15] and is
required for the development of nuocytes [16] which are
lymphoid-derived innate cells that contribute to the development
of asthmatic responses in mouse models of asthma [17]. Nuocytes
are activated by binding of IL-33 to its receptor ST2 (IL-1RL1)
and these cells are a major source of IL-5 and IL-13 in the lung
[18]. Thus, the asthma loci IL33, IL1RL1/IL18R1, RORA, and
IL13 previously identified by GWAS belong to the same pathway,
and could modify airway inflammation and interleukin responses
that are crucial for the development of asthma [1,19]. A meta-
analysis of GWAS data has confirmed the putative role of
common genetic variation within RORA in asthma susceptibility of
European Americans [20]. Moreover, a recent GWAS for lung
function identified a SNP (rs1902618) within the intron 1 of RORA
as a possible predictor of age-related decrease in forced expiratory
volume in 1 second (FEV1) [21].
Common genetic variations as analyzed in the GWAS do not
explain a substantial proportion of the missing heritability and the
disease risk, and therefore epistasis has been proposed as a possible
factor [22]. In this framework, several susceptibility alleles of low-
to-moderate-effects may modify the disease risk, especially when
the candidate genes belong to common biological pathways
[23,24]. We propose that RORA may interact with the G protein-
coupled Neuropeptide S Receptor 1 (NPSR1) pathway. NPSR1
and its ligand Neuropeptide S (NPS) are mostly expressed in
specific brain regions and affect multiple neuroendocrine and
behavioral responses [25–29]. NPSR1 was identified as a suscep-
tibility gene for asthma and related traits by positional cloning and
has been replicated in several independent association studies [30–
36], and marginally supported by GWAS [1]. In addition, NPSR1
SNPs have shown genetic associations with other inflammatory
phenotypes such as inflammatory bowel disease [37], and
rheumatoid arthritis [38,39]. Surprisingly, the functional NPSR1
SNP rs324981, encoding a substitution of Asn(107)Ile in the
putative ligand-binding pocket of NPSR1, was associated with
bedtime and sleepiness in a GWAS for sleep and circadian
phenotypes [40]. As phenotypical analysis of Npsr1 knockout mice
have thereafter revealed deficits in circadian locomotor activity
[41,42], we hypothesized that the NPS/NPSR1 pathway might
regulate RORA and other circadian clock genes. Expression of the
circadian clock genes oscillates in the hypothalamus by positive
and negative transcription/translation feedback loops to govern
the endogenous rhythms as well as the extent of inflammation and
cytokine balance through hormonal and neuronal connections
[43–45]. Taken together, both RORA and the NPS/NPSR1
pathway appear to play a part in complex immune-related,
behavioral and circadian outcomes, which could all be controlled
by the circadian clock. Thus, the aims of this study were: 1) To
clarify the potential functional crosstalk between NPSR1 and
RORA; 2) To identify the impact of putative RORA risk alleles on
the susceptibility to asthma and allergic traits; and 3) To evaluate
potential gene-gene interaction (epistasis) between RORA and
NPSR1 polymorphisms as risk factors for asthma.
Results
Stimulation of NPSR1 with NPS Regulates mRNA
Expression of RORA and Other Circadian Clock Genes
Human SH-SY5Y neuroblastoma cells over-expressing NPSR1
were stimulated with 100 nM NPS for 0–24 h and the mRNA
expression of RORA was measured using real-time PCR
(Figure 1a). NPS stimulation increased the expression of RORA
in SH-SY5Y cells over-expressing NPSR1 in a time and dose
dependent manner, and the effect could be partly inhibited by the
selective antagonist of NPSR1, SHA 68 (N-[(4-fluorophenyl)-
methyl]tetrahydro-3-oxo-1,1-diphenyl-3H-oxazolo[3,4-a]pyra-
zine-7(1H)-carboxamide) (Figure 1a and File S1) [46]. These
effects were not detected in the parental cell line with very low
endogenous NPSR1 expression (data not shown). One of the well-
known functions of RORA is the regulation of the circadian clock
machinery [43], where it competes with its binding partner
NR1D1 (nuclear receptor subfamily 1, group D, member 1) for
initiation/inhibition of ARNTL (aryl hydrocarbon receptor
nuclear translocator-like) transcription. Since NPS stimulation
up-regulated RORA expression, we measured the effects of NPS on
other components of the clock machinery including NPAS2
(Neuronal PAS domain-containing protein 2), PER1 (period 1),
CRY1 (cryptochrome 1) and DBP (D site albumin promoter
binding protein). NPAS2 can replace CLOCK (circadian
locomoter output cycles kaput), and PER1 and CRY1 are
regulated by dimerization of the core clock components ARNTL
(also known as BMAL1) and CLOCK/NPAS2. As shown in
Figure 1a, the expression of core clock components NPAS2,
PER1, and CRY1 was clearly increased after NPS stimulation. In
line with this, the expression of DBP, an important output gene of
the clock, was down-regulated after NPS challenge. The effects of
NPS on NR1D1, CLOCK and ARNTL expression were less
apparent. The results obtained in the human embryonic kidney
epithelial cell line (HEK293H cells) stably over-expressing
NPSR1-A confirmed the dose-dependent regulation of RORA
mRNA and related circadian clock genes 6 h after NPS
stimulation (Figure 1b). These results indicated that RORA is
regulated by the NPS/NPSR1 signaling pathway and suggested
a new regulator of circadian clock gene expression.
RORA Regulates NPSR1 Promoter Activity
The NPSR1 promoter is predicted to have a RORE binding site
(Figure 1c) in the minus strand with a matrix similarity of 0.92
out of 1.0 for RORA and it is found by at least three different
prediction methods (MatInspector, Consite, and PScan). To study
the effects of RORA on NPSR1 promoter activity, HeLa cells were
co-transfected with (1) the NPSR1 promoter coupled to a firefly
luciferase reporter gene, (2) the plasmid encoding the Renilla
luciferase, and (3) either the plasmid encoding the cDNA for
RORA-1 (pCMV6-XL5-RORA1) or the plasmid without RORA-
1 (pCMV6-XL5) used as a control. As shown in Figure 1d, over-
expression of RORA-1 led to a significant decrease (37.8610%;
mean6SD) in the luciferase levels compared to the cells co-
transfected with the vector without RORA-1. This suggests that
RORA-1 binds to the NPSR1 promoter and down-regulates its
activity. This could establish a negative regulatory loop cycling
with the circadian oscillation.
Rora mRNA Expression is Altered in the Lung Tissue of
Npsr1 Deficient Mice
To address the question whether Npsr1 knockdown has effects
on Rora expression in vivo, we collected lung tissue at 4 h intervals
from Npsr12/2 and wildtype mice during a 24 h period, and
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measured Rora mRNA expression with real-time PCR. As shown
in Figure 2A, expression of Rora is different between wildtype and
Npsr1 deficient mice (n = 3–4/group/timepoint). Because Rora
mRNA expression was significantly lower in Npsr12/2 mice in
comparison to wildtype littermates at the beginning of the light
period (subjective night) (Figure 2A), we verified the results in
a separated experiment using a larger group of mice (n = 6/group).
Lung samples were collected during the early hours (8–12 am) of
the light period. The results confirmed the lower expression of Rora
in the lung tissue of the Npsr12/2 mice (Figure 2B) and correlated
with the observed diurnal expression of Rora.
Polymorphisms in RORA are Associated with Asthma but
not with Atopic Sensitization
A total of 35 SNPs in RORA were analyzed for associations with
asthma and allergy-related traits in the prospective Swedish birth-
cohort BAMSE (n= 2033) and a subset of the European
multicenter cross-sectional study PARSIFAL (n= 1120),
(Figure 3). The SNPs spanned a region of 116.5 kb on
chromosome 15q22.2 and tagged the genetic variation in linkage
disequilibrium (LD) with the previously associated GWAS SNP
rs11071559 (Figure 4). We first investigated the association
between SNPs in RORA and physician-diagnosed childhood
asthma and other allergic traits in BAMSE and PARSIFAL as
independent datasets. The prevalence of the 35 RORA SNPs in
cases and controls, and the results of the allelic association tests
with asthma, wheezing, rhinitis and atopic sensitization are
presented in File S2.
In BAMSE, seven RORA polymorphisms were associated with
the diagnosis of asthma up to 4 years (rs7164773, rs8024629,
rs17191596, rs12437690, rs9302215, rs17204454 and rs341392)
(Figure 5a). Three of these SNPs (rs7164773, rs12437690,
Figure 1. Cross-talk of RORA and NPSR1 in cell models. (A) Real-time PCR analysis of circadian clock genes in human SH-SY5Y neuroblastoma
cell line over-expressing NPSR1 stimulated with 100 nM NPS for 0–24 h in the presence or absence of 3 mM SHA 68 (N-[(4-fluorophenyl)methyl]te-
trahydro-3-oxo-1,1-diphenyl-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide), a selective antagonist of NPSR1. (B) Real-time PCR analysis of RORA,
NR1D1, NPAS2, CLOCK, ARNTL, PER1, CRY1, and DBP mRNA expression in human embryonic kidney epithelial HEK-293H cell line over-expressing NPSR1
6 h after NPS (0.1–5 mM) stimulation. The results are presented as fold-changes in comparison to the unstimulated cells. GAPDH was used as the
endogenous reference, and data are expressed as mean of triplicate samples 695% confidence intervals. In all experiments, results were calculated
with the comparative DDCt method. (C) Schema of the NPSR1 promoter and the location of the putative 6-bp AT-rich sequence preceding the half-
core motif PuGGTCA (RORE). (D) NPSR1 driven luciferase in relative luminescence units after transfection with either RORA-1 encoding plasmid or an
empty vector. Ten biological replicates per group. Mann-Whitney U test ***p,0.0001.
doi:10.1371/journal.pone.0060111.g001
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rs341392) remained associated with the diagnosis of asthma at 8
years (Figure 5b). Of these, the SNP rs7164773 previously not
associated with asthma gave the most significant association signal
in BAMSE. There were some associations between RORA SNPs
and atopic sensitization at 8 years, rhinitis at 8 years and wheezing
up to 4 years, but all of them were of borderline significance,
suggesting that in this population RORA is mainly associated with
the diagnosis of childhood asthma rather than atopic-traits (File
S2). Similar results were found in PARSIFAL, where four RORA
SNPs were associated with physician-diagnosed asthma between 5
Figure 2. Expression of Rora in the lung tissue of wildtype (WT) and Npsr1 deficient (Npsr12/2) mice. (A) Lung tissue was collected from
WT and Npsr12/2 mice at 4 h intervals, and diurnal mRNA expression of Rora was measured with real-time PCR (n = 3–4/group/timepoint). The black
bar represents the dark period. (B) Expression of Rora in the lung tissue of wildtype and Npsr12/2 mice during the light period (8–12 am) (n = 6). Data
are expressed as relative units indicating a fold change in Rora mRNA expression that is normalized to an endogenous reference gene (18S ribosomal
RNA) and is relative to the non-template control calibrator (mean 6 SEM). Similar data were obtained in two separate experiments. *p,0.05.
doi:10.1371/journal.pone.0060111.g002
Figure 3. Flow chart with the distribution of cases and controls in the studied populations: BAMSE, PARSIFAL and the combined
dataset. Numbers within parenthesis indicate number of children, either as a total or by the presence of a given phenotype (cases/controls).
doi:10.1371/journal.pone.0060111.g003
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and 13 years of age (rs11071559, rs4775292, rs17204426 and
rs12438866) (Figure 5c), but there were no associations between
RORA SNPs and wheezing, rhinoconjuntivitis or atopic sensitiza-
tion. The GWAS SNP rs11071559 (C.T) was the lead SNP for
association with asthma in PARSIFAL as a separate dataset. In the
combined BAMSE-PARSIFAL dataset, five RORA SNPs including
the GWAS rs11071559 were associated with physician-diagnosed
asthma and remained significant after adjustment by country of
origin (Figure 5d). Interestingly, none of the RORA SNPs were
significantly associated with wheezing, rhinitis or atopic sensitiza-
tion in the combined dataset (File S2). The asthma-associated
SNPs, albeit different between BAMSE and PARSIFAL, were
confined into a region of 49 kb in the intron 1 of RORA
(chr15:61020254–61069988) and their effects were mainly de-
tected under dominant and additive models (File S3). A summary
of the most significant RORA SNPs associated with asthma is
presented in Table 1. The RORA rs7164773 was the lead SNP in
the combined dataset and carriers of one (TC) or two copies (CC)
of the rare allele had an increased risk for a physician-diagnosis of
asthma (Figure 6). The association between the lead SNP
rs7164773 and asthma was significant after adjustment for the
other asthma-associated SNPs RORA rs11071559 and RORA
rs341392. The RORA rs11071559 remained marginally associated
after adjustment by the lead SNP rs7164773. On the other hand,
the association of the RORA rs341392 disappeared when adjusting
for the lead SNP rs7164773 and for the RORA rs11071559.
Further information on the genotype distribution in asthmatic
cases and controls is presented in File S4.
Epistasis between RORA and NPSR1 Modify the Risk of
Asthma
Based on the results indicating up-regulation of RORA mRNA
expression after NPS stimulation of NPSR1 over-expressing
cells, and the observation that NPSR1 is down-regulated by
RORA, we studied the effects of gene-gene interaction between
RORA and NPSR1 SNPs on the risk of asthma. Eight NPSR1
SNPs [47] spanning a region of 191 kb on chromosome 7p14.3,
Figure 4. Overview of the genomic location and correlations of the RORA SNPs analyzed in this study. (A) Schematic representation of
the exon intron distribution of the longest isoform of RORA (NM_134231) located in chromosome 15q22.2 and the position of the GWAS SNP
rs11071559. An expansion of the 116.5 kb region surrounding the rs11071559 reveals the 35 SNPs analyzed in this study according to their positions
along the intron 1. (B) The LD structure of the 116.5 kb region of RORA as defined by the solid spine algorithm in the combined dataset (n = 3153).
Numbers in each box correspond to the pair-wise linkage disequilibrium coefficients (D’) between the respective SNPs. A similar LD structure was
observed in BAMSE and PARSIFAL as separated populations. Additional information on the 35 RORA SNPs is presented in Table S3.
doi:10.1371/journal.pone.0060111.g004
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and including the predicted NPSR1 promoter and the coding
region, were selected for the gene-gene interaction analysis
based on their minor allele frequencies and previous experi-
mental evidence supporting that some of the SNPs have
functional effects on NPSR1 expression and/or signaling
(Figure 7a). Allele and genotype distributions for the NPSR1
SNPs in the combined BAMSE-PARSIFAL material are
presented in Table S1. An overview of the significant SNP-
SNP interactions between NPSR1 (8 SNPs) and RORA (35 SNPs)
is presented in Figure 7a. We found significant interactions
between three non-synonymous SNPs in NPSR1, namely
rs34705969 (Cys197Phe), rs727162 (Ser241Arg) and rs6972158
(Gln344Arg) and three RORA SNPs (rs17191582, rs6494221 and
rs12899193) (Figure 7a). A second hub of strong interaction
signals was found between three SNPs located in the NPSR1
promoter (rs1963499, rs2168890 and rs2530547) and the RORA
SNP rs746241. An additional interaction signal was detected
between the NPSR1 promoter SNP rs2530547 and RORA
rs2899662 (Figure 7a). Interestingly, these RORA SNPs did not
show any significant main effects on asthma, but they had
significant effects on asthma susceptibility dependent on NPSR1.
Furthermore, we identified significant interactions between the
RORA SNP rs7164773, which showed the most significant SNP
main effect on childhood asthma, both at 4 and 8 years in
BAMSE, and two coding SNPs in the NPSR1 gene, i.e.,
rs34705969 (Interaction p= 0.005) and rs6972158 (Interaction
p= 0.001). These results suggest that the effects of RORA SNPs
as risk factors for asthma may differ depending on the NPSR1
genotype. An example is illustrated in Figure 7b for RORA
rs7164773 and NPSR1 rs6972158. The CC genotype in RORA
rs7164773 only confers risk for asthma in carriers of one or two
copies of the rare allele G in NPSR1 rs6972158, encoding for
a substitution of glutamine by arginine in exon 9 (OR 2.45,
1.56–3.85, p = 0.00009) but not in the homozygotes for the
wild-type NPSR1 allele A (OR 1.02, 0.66–1.58, p= 0.91). Taken
together, we showed that combinations of common susceptibility
alleles (in RORA) and less common functional polymorphisms (in
NPSR1) could modify the joint risk effect on asthma suscepti-
bility.
To further interpret the significance of the gene-gene
interactions between RORA and NPSR1 in terms of functional
effects on signal transduction, we investigated the interactions
between RORA SNPs and a functional haplotype in NPSR1 that
showed significant association with reduced risk of inflammatory
bowel disease in a previous study [47]. The haplotype CAC is
a combination of SNPs in NPSR1 containing the alleles
rs2530547C/rs324981A/rs727162C (Figure 7a); it is found
in 9.2% of the population, and corresponds to increased NPSR1
mRNA expression (2103C) and weaker intracellular signaling
(107Asn and Ser241). Although this haplotype was not
associated with asthma, significant effects in increasing asthma
risk become evident if the haplotype CAC coincided with the
rare alleles of the SNPs rs8024629 and rs9302215 in RORA
(Figure 7c). The RORA SNP rs8024629, only showed
significant main effects for physician-diagnosed asthma by age 4
years (Table 1 and File S4), but it might also increase the
risk for asthma in the combined dataset in the co-occurrence
with the functional NPSR1 haplotype CAC (OR 2.63, 1.30–
5.34; p = 0.007). Similar effects were found for the RORA SNP
rs9302215, with only marginal main effects on the risk of
physician-diagnosed asthma by age 4 years (Files S2, S3, S4),
but that in combination with the functional haplotype of NPSR1
might significantly increase the risk for asthma in children (OR
2.88; 1.33–6.23, p= 0.007) (Figure 7c).
Table 1. The RORA SNPs associated with asthma and their effects under additive and dominant models.
Dominant Additive*
dbSNP Genotypes{ Associated phenotype OR (95%CI), P value P value Dataset SNP effect
Distance in
kb**
EM
D prime**
rs8024629 CC/CA/AA Asthma up to 4 years 1.54 (1.15–2.53) 0.003 0.02 B Increase risk 47.6 0.88
Asthma up to 8 years 1.34 (1.03–1.75) 0.02 ns B
rs17191596 TT/TC/CC Asthma up to 4 years 1.57 (1.16–2.13) 0.003 0.02 B Increase risk 32.1 0.92
Asthma up to 8 years 1.29 (0.97–1.71) 0.07 ns B
rs12437690 GG/GA/AA Asthma up to 4 years 1.58 (1.16–2.17) 0.004 0.001 B Increase risk 12.5 0.89
Asthma up to 8 years 1.42 (1.08–1.87) 0.01 0.004 B
rs7164773 TT/TC/CC Asthma up to 4 years 1.79 (1.24–2.60) 0.002 0.001 B Increase risk – –
Asthma up to 8 years 1.79 (1.29–2.48) 0.0004 0.0004 B
Asthma ever 1.47 (1.13–1.91) 0.003 0.004 C
rs12438866 TT/TC/CC Asthma 5–13 years 0.63 (0.43–0.91) 0.01 0.04 P Protective 0.57 0.31
rs11071559 CC/CT/TT Asthma 5–13 years 0.53 (0.32–0.87) 0.01 0.01 P Protective 2.04 0.92
Asthma ever 0.71 (0.55–0.92) 0.01 0.007 C
rs341392 AA/AC/CC Asthma up to 4 years 0.69 (0.51–0.92) 0.01 0.02 B Protective 56.2 0.30
Asthma up to 8 years 0.69 (0.53–0.89) 0.005 0.005 B
Asthma ever 0.71 (0.58–0.89) 0.004 0.01 C
*Exact Armitage P value.
B: Bamse; P: Parsifal, C: combined;
{Rare homozygotes are in bold.
EM: Expectation-Maximization **From the lead SNP rs7164773.
Further information on the genotype distributions is presented in File S3 and File S4.
ns: non-significant.
doi:10.1371/journal.pone.0060111.t001
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Discussion
Here, we present evidence of functional and gene-gene
interaction between RORA and NPSR1. Even though RORA
was recently identified as an asthma susceptibility gene in a GWAS
study [1], its role in asthma pathogenesis is unknown. Using cell
models, we found that RORA is up-regulated upon activation of the
NPS-NPSR1 signaling pathway and that RORA, acting as
a suppressor factor, may regulate the activity of the NPSR1
promoter. Several biological functions, including inflammation
and neuronal physiology, are expected to be influenced by the
functional link between RORA and NPSR1 [3,48,49]. Interest-
ingly, the expression of other genes involved in the circadian clock
(e.g. NPAS2, PER1 and CRY1) was also up-regulated after
stimulation of the NPS/NPSR1 pathway. Furthermore, Rora
mRNA expression was significantly lower in the lung tissue of
Npsr1 deficient mice when compared to wildtype littermates. The
results of the genetic association tests and the gene-gene
interaction analysis confirmed that polymorphisms in RORA are
associated with asthma but their effects may increase or decrease
depending on the convergence with polymorphisms in the
promoter and the exons of NPSR1. Altogether, this study provides
evidence of a previously unknown connection between RORA
and NPSR1 that involve the regulation of the circadian clock. The
gene-gene interaction analysis indicated that particular combina-
tions of common susceptibility alleles (amenable to be detected by
GWAS approaches), together with less common functional
polymorphisms may modify the effects of a given risk allele on
asthma susceptibility.
The genetic association between RORA rs11071559 and asthma
susceptibility was identified in a GWAS of individuals with
European descent [1], and further confirmed in other populations
[20,50]. However, in-depth association analyses of RORA SNPs
covering the asthma-associated region have not been done. We
conducted a genetic association study evaluating the effects of 35
polymorphisms in RORA as risk factors for asthma and allergy-
related traits in two independent European sample sets. Here, we
replicate the effects of RORA rs11071559 on asthma-susceptibility
Figure 5. Allelic association tests between RORA SNPs and asthma. SNPs are represented by dots in relation to their genomic position. Grey-
colored dots have a degree of linkage disequilibrium (r2) between 0.40 and 0.60 with the lead SNP (diamond). Recombination rate is indicated as
a continuous line. Dashed line represents the significance threshold. (A) Asthma ever up to 4 years in BAMSE; (B) Asthma ever up to 8 years in BAMSE;
(C) Physician-diagnosed asthma ever between 5–13 years in PARSIFAL; (D) Physician-diagnosed asthma in the combined dataset.
doi:10.1371/journal.pone.0060111.g005
Interaction between RORA and NPSR1 in Asthma
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e60111
and discover additional asthma-susceptibility alleles in the
surroundings of this SNP. The fact that the association signals
were found in two separate datasets of European children and
were further observed in the combined dataset support RORA as
a susceptibility gene for asthma. Although the associated SNPs
were different between BAMSE and PARSIFAL datasets, the
most significant signals were driven by SNPs narrowed to a 49 kb
region surrounding the SNP rs11071559. In addition, the effects of
RORA susceptibility alleles might be age-dependent as suggested
by stronger associations in BAMSE compared to PARSIFAL. In
BAMSE, 77% of asthmatic children were diagnosed before or by
the age of four years (Figure 3). However, the PARSIFAL
dataset include children with a physician-diagnosis of asthma ever
up to age thirteen, and we may expect a broader spectrum of
molecular phenotypes of asthma. This may have influenced our
results because phenotype heterogeneity is an important source of
confounding in genetic association studies [51], and different
pathways are involved in determining early-onset vs. late onset
wheezing phenotypes [52]. Further explanations include popula-
tion sub-structure and power limitations by a smaller sample size
in PARSIFAL. Nevertheless, significant allele and genotype
associations were detected between the GWAS rs11071559 and
physician-diagnosed asthma in PARSIFAL when analyzed as
separated dataset. The indications that RORA may be related with
early-onset asthma were also suggested by findings within the
BAMSE cohort showing that the risk effects of some RORA SNPs
(rs8024629, rs17191596, rs12431690) were stronger for asthma
cases diagnosed by age 4 in comparison to cases at age 8 (File S4).
Although the underlying mechanisms are unknown, the functional
link of RORA with the pathogenesis of early-onset asthma might
involve alterations in lung development [12].
The observation that RORA down-regulated the NPSR1
promoter, together with the up-regulation of clock genes (including
RORA) upon NPSR1 stimulation, led us to hypothesize that
RORA could have biological interactions with NPSR1. In cell
models, the effect of NPS-stimulation on RORA mRNA was
modest, but it could be inhibited by a selective NPSR1 receptor
antagonist and was dose-dependent (Figure 1a and File S1).
Moreover, this effect was clearly specific for the NPS/NPSR1-
pathway since RORA mRNA was not up-regulated in NPS-
stimulated cells with low NPSR1 expression (data not shown). The
fact that NPSR1 stimulation led to up-regulation of RORA mRNA
and other clock genes is in agreement with the hypothesis
suggesting that alterations in the expression of clock genes might
lead to circadian disruption and immune dysregulation in chronic
inflammatory diseases such as inflammatory bowel disease [53,54]
and rheumatoid arthritis [55,56]. The increase in the expression of
clock genes after NPS stimulation might not be directly related to
the development of asthma, but might influence several in-
flammatory processes related to the disease. There is an increasing
number of studies showing that clock genes play an important part
in modulating inflammation [45,57–59] and indeed, the hallmarks
of asthma, namely chronic inflammation, airway hyper-respon-
siveness and reversible airway obstruction, exhibit 24 h fluctua-
tions with worsening around 4 AM in comparison to 4 PM [60].
Our results in the lung tissue of wildtype and Npsr1 deficient mice
showed that Rora was expressed in a time-dependent fashion and
the expression was significantly lower in the lung tissue of Npsr12/
2 mice during the early hours of the light period. It is tempting to
Figure 6. Genotype associations between RORA SNP rs7164773 and physician-diagnosed asthma.
doi:10.1371/journal.pone.0060111.g006
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speculate that the genetic associations of NPSR1 SNPs with
chronic inflammatory diseases might be related to dysregulation of
neuroimmune-endocrine pathways controlled by the clock genes.
Since both RORA and NPSR1 are independently associated
with asthma, we evaluated the potential epistasis between
polymorphisms in these genes (‘gene-gene interactions’). The
analyses were conducted in the combined dataset which allowed us
to gain statistical power and increase the accuracy of the estimates.
Four NPSR1 SNPs included in the interaction analysis were
selected based on experimental evidence of functional effects on
gene expression or downstream signaling [47]. The promoter
NPSR1 SNP rs2530547 (2103) significantly affected luciferase
expression in gene reporter assays and NPSR1 mRNA levels in
human leukocytes, whereas the non-synonymous NPSR1 SNPs
(rs324981/Ile107Asn, rs34705969/Cys197Phe, rs727162/Ser241-
Arg) affected NPS-induced genome-wide transcriptional profiles
(including the clock genes PER1, PER2 and ARNTL) and CRE-
dependent luciferase activities in transfected human cell lines [47].
The substitution of Cysteine 197 Phenylalanine even exhibited
a loss-of-function phenotype in these studies. In addition, we
included three additional SNPs in the promoter region of NPSR1
and a non-synonymous SNP (rs6972158) in NPSR1 with unknown
function but potential to affect transcription factor binding or
signal transduction, respectively. The epistasis between NPSR1 and
RORA include three exonic NPSR1 SNPs (rs34705969, rs727162,
rs6972158) and intronic RORA SNPs (Figure 7a). Notably, the
association of RORA rs7164773 with asthma might depend on the
convergence with rare alleles of the NPSR1 SNPs rs6972158 on
chromosome 7 (Figure 7b). Similar results were observed for
RORA SNP rs8024629 and RORA SNP rs9302215 which only
increase the risk of asthma in individuals carrying the functional
haplotype CAC in NPSR1 (rs2530547C/rs324981A/rs727162C)
(Figure 7c). This haplotype might reduce the expression of
downstream target genes, such as RORA.
The fact that well-replicated asthma candidate genes (i.e., IL4,
GSTP1, STAT6, ADRB2, TNF, TGFB1, etc) [61] are not listed as
GWAS hits, and that low-ranked SNPs contribute to predict
asthma-related phenotypes in children [52], suggests that gene-
gene interactions, gene-environment interactions and epigenetics
may be of relevance. It is now more clear that genome-wide
association studies may detect the effect of common polymorph-
isms but cannot detect the effects of less frequent coding mutations
Figure 7. Gene-gene interactions between RORA and NPSR1. (A) Heatmap of the p-values for interaction between 35 RORA SNPs (y-axis) and 8
NPSR1 SNPs (x-axis). A schema of the NPSR1 gene is presented at the bottom of the figure with the relative positions of the SNPs. The alleles
comprising the CAC haplotype are marked in red. (B) Effects of one (TC) or two copies (CC) of the RORA SNP rs7164773 on asthma risk according to
the genotypes on the NPSR1 SNP rs6972158 (Gln344Arg). Bars represent 95% confidence intervals. (C) Effects of RORA rs8024629 and RORA rs9302215
on asthma risk according to the functional NPSR1 haplotype CAC (rs2530547C/rs324981A/rs727162C). All the results for gene-gene interactions
analysis are presented after adjustment by age and country of origin.
doi:10.1371/journal.pone.0060111.g007
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and low frequency functional SNPs. In this sense, RORA might be
the proxy for a pathway, where other genes may be involved but
their effects are difficult to detect in the GWAS approach. Epistasis
and particular intragenic and intergenic allele combinations are
important elements in predicting disease risk and may explain
a large proportion of the missing heritability [22]. Under this
‘‘combinatory effect’’ it is required that several variants coincide
and affect a biological pathway. The phenotype will be driven by
the multiplicative effect of variants conditioning a deleterious
outcome. Given the redundancy of the biological systems it is
feasible that a large fraction of individuals may carry several
susceptibility alleles, but depending on the combinations, the
outcome of each allele may increase, decrease or become
neutralized. The fact that the associations between RORA and
asthma are detected in GWAS including a European-American
population but not identified in African-American and African-
Caribbean samples [20] highlight that the genetic context might
determine the effects of any given allele.
In conclusion, genetic polymorphisms in RORA are risk factors
for childhood asthma and have epistasis with polymorphisms in
NPSR1. The NPS/NPSR1 pathway has biological interactions
with RORA and other circadian clock genes which could have
effects on the rhythmic occurrence of asthma symptoms. The
effect of the susceptibility alleles may depend on particular
combinations with one or more genotypes in other genes
belonging to similar biological pathways, and could in part
explain the complex relationships and contradictions leading to
the asthma phenotype.
Materials and Methods
Ethics Statement
All the samples were analyzed anonymously. The BAMSE study
was approved by the Ethics Committee of Karolinska Institutet,
Stockholm, Sweden, and regarding PARSIFAL children, ethical
approval for the study, including genetic analyses, was obtained in
each country. Written informed consent was obtained from the
parents and/or legal guardians.
Study Population
Genetic association studies were conducted in 2033 children
(age 8 years) from the prospective Swedish birth-cohort BAMSE
[62,63], and 1120 children (age 5–13 years) from the European
multicenter cross-sectional study PARSIFAL [64]. The selected
dataset from the PARSIFAL study includes the two control
groups, which have more comparable demographic characteristics
to the BAMSE birth cohort than the farmer and Steiner school
children. A schematic representation of the phenotypes analyzed
in this study and the distribution of cases and controls is presented
in Figure 3. The effects of individual SNPs on asthma risk were
evaluated in BAMSE and PARSIFAL separately as well as in the
combined BAMSE-PARSIFAL dataset (n = 3153).
Phenotype Assessment
In both datasets, information on the clinical outcomes was
obtained from questionnaires filled by the parents, except for
atopic sensitization which was assessed from plasma samples. In
BAMSE, Asthma ever up to 4 years was defined as a physician-
diagnosed asthma after 3 months of life and up to 4 years of age.
Asthma ever up to 8 years was defined as a physician-diagnosed
asthma after 3 months of life and up to 8 years of age.Wheezing at 4
years was considered with at least 1 episode of wheeze during the
last 12 months prior to the questionnaire of the 4th year. Rhinitis at
8 years was diagnosed if the children had episodes of prolonged
sneezing or a runny or blocked nose without a common cold in the
last 12 months prior to date of questionnaire 8. Atopic sensitization
was considered present if a child had levels of allergen-specific IgE
.0.35 kU/L to PhadiatopH, a mixture of cat, dog, horse, birch,
timothy, mugwort, Dermatophagoides pteronyssinus, and Cladosporium
allergens; (ImmunoCAPTM, Thermo Fisher Scientific, Phadia AB,
Uppsala, Sweden). In PARSIFAL, physician-diagnosed asthma was
considered to be present for children reporting ever having been
diagnosed with asthma, or with obstructive bronchitis more than
once. Current wheezing was defined as at least one episode of
wheezing during the last 12 months. Current rhinoconjunctivitis
symptoms were defined as sneezing, runny nose, nasal block-up
and itchy eyes in the child during the last 12 months without
having a cold at the same time. Atopic sensitization was defined as at
least one allergen-specific serum IgE test $0.35 kU/L against
a mixture of common inhalant allergens (PhadiatopH). To define
the phenotypes for the combined dataset, corresponding outcomes
in BAMSE and PARSIFAL were combined as presented in
Figure 3.
SNP Selection, Genotyping and QC
A total of 37 SNPs were genotyped in RORA. The SNPs were
selected using the tagger algorithm implemented in Haploview
[65]. The aim was to analyze the common polymorphisms in the
surroundings of the GWAS SNP rs11071559 and refine the
genomic interval with the strongest association signals. Primers for
multiplex PCR and extension reactions were designed by the
SpectroDesigner software (Sequenom GmbH, San Diego, CA,
USA) (Table S2). PCR and extension reactions were performed
according to manufacturer’s standard protocols. The SNP analysis
was performed by MALDI-TOF mass spectrometry (matrix-
assisted laser desorption/ionisation-time of flight; Sequenom
GmbH). Each assay was validated using 24 unrelated Caucasians
and 3 CEPH DNA samples as well as 14 trios from the CEU
population. Based on successful genotyping 35 SNPs were
included for association tests (two RORA SNPs, namely
rs12591749 and rs1820357 were excluded by failure during
genotyping). Success rate for genotyping was 98.8% in BAMSE
and 97% in PARSIFAL. For NPSR1 (MIM: 608595), eight SNPs
were genotyped in BAMSE and PARSIFAL as aforementioned.
The SNPs were selected according to their minor allele frequencies
(MAF$0.02) and the assumption that polymorphisms in the
regulatory and coding gene region are the best candidates to play
a causative role in gene function. Previous experimental evidence
supports that some of the SNPs have functional effects on NPSR1
expression and/or signaling [47]. The selected polymorphisms
included four variants in the predicted promoter and four non-
synonymous polymorphisms rs324981 (Ile107Asn); rs34705969
(Phe197Cys); rs727162 (Ser241Arg) and 6972158 (Gln344Arg).
Genotype frequencies for all SNPs agreed with the expectations
under Hardy-Weinberg equilibrium (Table S3).
Genetic Association Tests
Linkage disequilibrium among the SNPs was calculated in each
dataset and in the combined dataset (n = 3153) using the
normalized measure of allelic association (D’) implemented in
Haploview (http://www.broad.mit.edu/mpg/haploview). Genetic
association test were conducted using the SVS v7.6.9 software
(Golden Helix Inc.). SNPs were filtered out if call rates (,0.85) and
if the Hardy-Weinberg Equilibrium in controls reached
(p,0.0001) under x2 test and/or Fisher exact test. Basic allelic
effects were analyzed by 262 allele-count tests and with the Exact
Cochran-Armitage test (assuming near-additive risk). Genotype
associations were evaluated under genotypic, additive, dominant,
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and recessive models. Logistic regression was used to model the
effects of one copy (heterozygotes) or two copies (homozygotes) of
the mutant allele on asthma status having the wild type genotype
as reference category after adjustment by country-of-origin, age
category and gender in the independent analysis of PARSIFAL
(n = 1120) and in the combined BAMSE-PARSIFAL dataset
(n = 3153). When the numbers of rare homozygotes preclude
association tests, they were combined with the heterozygotes and
the effect of the SNP analyzed in a dominant model (rare
homozygote+heterozygote vs. wild-type homozygote). A P value
#0.05 was considered statistically significant. To take the multiple
tests performed into account the P value of allelic and genotype
association analyses are presented after 10.000 permutations. The
False Discovery Rate of the Exact Armitage test is reported for the
genetic association under additive model (File S3).
Cell Culture and NPS Stimulations
SH-SY5Y human neuroblastoma cells (ATCC, CRL-2266TM)
were grown in DMEM-GlutaMAXTM-I Medium (Invitrogen)
supplemented with 10% fetal calf serum, 100 U/ml penicillin and
100 U/ml streptomycin at 37uC in a 5% CO2 humidified
incubator. Transfections were done with FuGENE reagent
(Roche) according to the manufacturers protocols. For making
stable clones, SH-SY5Y cells were transfected with a NPSR1-A-
GFP plasmid and selected with 500 mg/ml of G418 for 3 weeks.
NPSR1-A was amplified from colon cDNA of healthy individuals
and fusion products of NPSR1-A with green fluorescent protein
(GFP) were made in pcDNA3.1/CT-GFP-TOPO (Invitrogen Life
technologies). The construct was verified by sequencing. For
RORA regulation studies, the SH-SY5Y cells over-expressing
NPSR1 and the SH-SY5Y cells with very low endogenous NPSR1
expression were seeded at 0.56106 cells/ml to 6-well plates. After
24 h, the clock was entrained with fresh cell media, and the cells
were either incubated with or without 100 nM NPS
(SFRNGVGTGMKKTSFQRAKS) (MedProbe, Oslo, Norway)
for 4 h, 8 h, 12 h, 16 h and 24 h or incubated with a dilution
series of NPS (0, 10 nM, 100 nM, 1 mM and 2 mM) for 4 h. SHA
68 (N-[(4-fluorophenyl)methyl]tetrahydro-3-oxo-1,1-diphenyl-3H-
oxazolo[3,4-a]pyrazine-7(1H)-carboxamide), a selective antagonist
of NPSR1 was synthetized as described previously at.95% purity
as determined by LC-MS [46], and 3 mM SHA 68 was added
10 min before NPS stimulation. Total cellular RNA was isolated
with the RNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse
transcription was performed with TaqMan reverse transcription
reagents (Applied Biosystems, Rotkreuz, Switzerland) using
random hexamers according to the manufacturer’s protocol.
The stable human embryonic kidney (HEK293) cell line over-
expressing NPSR1-A has been described elsewhere [66]. The cells
were cultured in 293 SFM II medium (Gibco/Invitrogen)
supplemented with penicillin/streptomycin and constantly cul-
tured under puromycin selection (0.8 mg/ml) (Sigma-Aldrich, St
Louise, MO, USA), seeded at 16106 cells/ml and treated with
NPS (1 nM–5 mM) for 6 h.
Npsr12/2 Mice
Eight weeks old Npsr12/2 male mice [29] or their wildtype male
siblings in BALB/c background (N9 with speed congenics) were
housed under standard 12-hour light-dark cycle conditions and
sacrificed by cervical dislocation at different time points. Lung
samples were collected and snap-frozen on dry ice. Total RNA
was extracted using Eurozol Reagent (EuroClone, Via Lombordia,
Italy) and reverse transcribed to cDNA. Rora mRNA expression
was measured as previously described [29]. Single-group compar-
isons were made using the unpaired Student’s t-test. Results are
expressed as mean 6 SEM. P-values ,0.05 were considered
statistically significant.
qPCR
The mRNA expression was measured with qRT–PCR using
SYBRH Green. The primer sequences are given in Table S4. The
PCR assay was performed in a total volume of 20 ml, containing
cDNA template, 10 ml SYBRH Green PCR Master Mix (Applied
Biosystems), 100 nM of each primer and 100 nM of GAPDH or
18S probes, using 7500 Fast Real-Time PCR system (Applied
Biosystems) with the following reaction conditions: 50uC for 2 min
and 94uC for 10 min; following 45 cycles of 92uC for 14 s and
1 min at 60uC. A dissociation stage was added to the SYBRH
Green reactions to confirm primer specificity. Relative quantifi-
cation and calculation of the range of confidence was performed
with the comparative DDCT method. In the cell line studies, results
are shown as relative expression compared with un-stimulated cells
and GAPDH (Applied Biosystems) was used as an endogenous
control. The variation in the Ct levels of GAPDH expression was
16.5260.35 (mean 6 SD, n= 48). In the mouse studies, data are
presented as relative units indicating a fold-change in Rora mRNA
expression that was normalized to 18S ribosomal RNA (Applied
Biosystems), and was relative to the non-template control
calibrator. The variation in the Ct levels of 18S expression was
10.6960.03 (mean 6 SD, n= 49) in the temporal expression
experiment (Figure 2A) and 8.6260.07 (n= 12) in the replication
dataset (Figure 2B).
Transcription Factor Binding Predictions
Prediction for RORA binding sites in NPSR1 promoter was
conducted using sequence-based methods and phylogenetic
approaches. Matrixes were retrieved from Transfac under ID.
T01527, T01528, T01529. Promoter of the human NPSR1 was
retrieved between 2499 to +200 from the Database of Eukaryotic
gene promoters (EPD) (http://epd.vital-it.ch/) and analyzed using
MatInspector (http://www.genomatix.de) and Consite (http://
asp.ii.uib.no:8090/cgi-bin/CONSITE/consite). Binding propen-
sity on the proximal region of NPSR1 2450 to +50 (NM_207173
and NM_207172) was calculated using PScan (http://159.149.
109.9/pscan/).
Luciferase Assays
To study the effects of RORA expression on the activity of the
NPSR1 promoter, HeLa cells (ATCC CCL2) were growth in
DMEM medium supplemented with 10% fetal calf serum and
penicillin-streptomycin at a density of 0.56106/well to 80–90%
confluence. Cells were co-transfected with 1 mg of the NPSR1
promoter coupled to firefly luciferase, 50 ng of pRL-TK Renilla
Luciferase reporter vector (Promega, Madison, WI, USA), and
500 ng of a plasmid encoding the cDNA for RORA1 (pCMV6-
XL5-RORA1, Origene Inc.). The control of this experiment were
the HeLa cells co-transfected with 500 ng of the vector pCMV6-
XL5 without RORA1 (Cat. PCMV6XL5, OriGene Inc).
Transfections were done using the XtremeGene 9 reagent in
a 3:1 ratio (Promega). Total cell lysates were prepared 24 h post
transfection using passive lysis. Luciferase activity was calculated
using the Dual-Luciferase Reporter Assay System (Promega)
according to manufacturer’s instructions, and a Microplate
Reader Infinite 200 (Tecan, Ma¨nnedorf, CH). Ten biological
replicates were included for each plasmid (RORA1 vs. vector
without RORA1). Firefly Luciferase activity was expressed in
luciferase units relative to the transfection with the empty vector,
after normalization for transfection efficiency based on values
obtained for Renilla Luciferase. To obtain a relative estimation of
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the activity of the NPSR1 promoter, each experiment was done in
parallel with co-transfections of HeLa cells with plasmids encoding
the transcription factor p53 (p53wt), the p53 responsive element
coupled to firefly luciferase (RE-luc) or both (p53wt+p53RE-luc).
Transfection of the p53RE-luc construct resulted in 4.7-fold more
luciferase activity when compared with the NPSR1 promoter
activity (data not shown).
Gene-gene Interactions
Eight NPSR1 SNPs were selected to conduct gene-gene
interaction test with 35 RORA SNPs in the combined dataset.
The NPSR1 SNPs included the promoter polymorphism
rs2530547 which affect NPSR1 gene expression and is located at
307 bp of a RORA binding site, as well as non-synonymous
polymorphisms rs324981 (Asn107Ile), rs727162 (Ser241Arg) and
rs34705969 (Cys197Phe) with a loss-of-function phenotype
(197Phe), which had effects on NPSR1 downstream signaling
[47]. In addition, the non-synonymous polymorphism rs6972158
(Gln344Arg) was selected for analyses. The interaction analysis
was performed in the pooled BAMSE-PARSIFAL dataset, in-
cluding 3153 children. A multiple logistic regression model was
used to test for gene–gene interaction between RORA and NPSR1
SNPs by adding an interaction term between the genotypes of
interest, using STATA (Statistical Software, Version 8.0, Collage
Station, TX, USA). A genetic model-free coding with indicator
(dummy) variables for common homozygous (coded 0), heterozy-
gous (coded 1) and rare homozygous (coded 2) was used as a first
approach to investigate the pattern of interaction between RORA
and NPSR1 genotypes. For analyses of SNPs with relatively low
minor allele frequency (thus few rare homozygotes) rare homo-
zygotes were combined with the heterozygotes and a dominant
genetic model was used. P-values for departure from a multiplica-
tive interaction model on the OR scale were obtained by
likelihood-ratio tests between the models with and without
interaction term. The regression models were adjusted for
country-of-origin and age. For the gene-gene interaction analysis
a P value #0.05 was considered statistically significant. However,
considering the number of comparisons performed (n = 280), we
focused on interactions with a P value #0.01.
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